Efficacy and safety of mavacamten intreatment of hypertrophic cardiomyopathy:a systematic review and meta-analysis: supplementary data 1

Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients withhypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane,and Scopus up to August 2022 for randomized studies reporting our pre-specified outcomes. Results: It wasobserved that mavacamten significantly improved New York Heart Association class (p < 0.009), ClinicalSummary Score of the Kansas City Cardiomyopathy Questionnaire (p = 0.02), post-exercise left ventricularoutflow tract gradient (p < 0.00001), functional end point (p = 0.05), and lowered septal reductiontherapy rates (p < 0.00001). However, there were no significant differences in the ≥1 severe adverseevents, ≥1 treatment-emergent adverse events, left ventricular volume index, left ventricular fillingpressure, left ventricular end-diastolic volume index, and peak oxygen uptake (pVO2). Conclusion: Futurelarge-scale trials are required to confirm our results and determine the long-term benefits and risks ofmavacamten use in these patients.